OpenURL Connection Search

Select item for more details and to access through your institution.

Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry.
Published in:
Archives of Dermatological Research, 2024, v. 316, n. 7, p. 1, doi. 10.1007/s00403-024-03122-w
By:
- Papp, Kim A.;
- Gooderham, Melinda;
- Lynde, Charles;
- Brassard, Danielle;
- Al-Mohammedi, Faisal;
- Prajapati, Vimal H.;
- Delorme, Isabelle;
- Albrecht, Lorne;
- Haydey, Richard;
- Alam, Maryam Shayesteh;
- Beecker, Jennifer;
- Siddha, Sanjay;
- Maguin, Marie;
- Farag, Mahmoud S.;
- Vieira, Antonio;
- Rihakova, Lenka;
- Langley, Richard G.
Publication type:
Article
Adalimumab Dose Intensification in Recalcitrant Hidradenitis Suppurativa/Acne Inversa.
Published in:
2020
By:
- Zouboulis, Christos C.;
- Hansen, Hendrik;
- Caposiena Caro, Raffaele Dante;
- Damiani, Giovanni;
- Delorme, Isabelle;
- Pascual, José Carlos;
- Reguiai, Ziad;
- Trigoni, Anastasia;
- Vilarrasa, Eva;
- Alfageme Roldán, Fernando;
- Zouboulis, Christos C;
- Caposiena Caro, Raffaele Dante;
- Pascual, José Carlos;
- Alfageme Roldán, Fernando
Publication type:
journal article
A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial.
Published in:
British Journal of Dermatology, 2020, v. 182, n. 6, p. 1348, doi. 10.1111/bjd.18851
By:
- Blauvelt, A.;
- Papp, K.;
- Gottlieb, A.;
- Jarell, A.;
- Reich, K.;
- Maari, C.;
- Gordon, K.B.;
- Ferris, L.K.;
- Langley, R.G.;
- Tada, Y.;
- Lima, R.G.;
- Elmaraghy, H.;
- Gallo, G.;
- Renda, L.;
- Park, S.Y.;
- Burge, R.;
- Bagel, J.;
- Vender, Ronald;
- Lomaga, Mark A.;
- Delorme, Isabelle
Publication type:
Article
Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry.
Published in:
Dermatology & Therapy, 2023, v. 13, n. 2, p. 535, doi. 10.1007/s13555-022-00870-3
By:
- Gooderham, Melinda;
- Papp, Kim A.;
- Lynde, Charles;
- Delorme, Isabelle;
- Beecker, Jennifer;
- Albrecht, Lorne;
- Dei-Cas, Ignacio;
- Brassard, Danielle;
- Prajapati, Vimal H.;
- Vieira, Antonio;
- Rihakova, Lenka
Publication type:
Article
Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America.
Published in:
2019
By:
- Papp, Kim A.;
- Gooderham, Melinda;
- Beecker, Jennifer;
- Lynde, Charles W.;
- Delorme, Isabelle;
- Dei-Cas, Ignacio;
- Albrecht, Lorne;
- Rampakakis, Emmanouil;
- Sampalis, John S.;
- Vieira, Antonio;
- Hussein, Shamiza;
- Chambenoit, Olivier;
- Rihakova, Lenka
Publication type:
journal article

Found: 5

Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry.

Adalimumab Dose Intensification in Recalcitrant Hidradenitis Suppurativa/Acne Inversa.

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial.

Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry.

Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America.